PIA
GYRE icon

Piedmont Investment Advisors’s Gyre Therapeutics GYRE Stock Holding History

Piedmont Investment Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27
Closed -$2K – 1560
2018
Q2 		$2K Buy
+27
New +$4.74K ﹤0.01% 2581

Other funds holding GYRE

NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Piedmont Investment Advisors's GYRE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Gyre Therapeutics (GYRE) in Q3 2018, closing a stake of 27 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in GYRE in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 70 funds tracked by Wall St. Rank hold GYRE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Gyre Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 27 Gyre Therapeutics shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Gyre Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Gyre Therapeutics position peaked at $2K in Q2 2018.
  • 70 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.